SMITH IAN F 4

What Happened
Ian F. Smith, CEO of Stoke Therapeutics (STOK), received two equity awards on February 17, 2026: a 193,000-share option-type award and a 129,000 restricted stock unit (RSU) award. Both awards were reported as acquired at $0.00 (standard grant awards, classified as derivative transactions). These are grants/compensation awards, not open‑market purchases or sales.

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (filed timely).
• Awarded amounts: 193,000 (option-style grant per footnote F1) and 129,000 RSUs (per footnotes F2/F3). Price reported: $0.00 (grant).
• Vesting for the 193,000 option-style award: 1/48 of the total award vests on March 15, 2026 and 1/48 on each monthly anniversary thereafter, subject to continued service (F1).
• Vesting for the 129,000 RSUs: 1/4 of the RSUs vest annually with the first tranche vesting on February 15, 2027; each RSU converts to one share upon settlement (F2, F3).
• Shares owned after the transaction: not specified in the provided excerpt—see the full Form 4 for post‑transaction holdings.
• No 10b5‑1 plan, tax‑withholding sale, or late‑filing flag noted in the provided details.

Context
These grants are typical executive compensation: RSUs convert to shares on vesting, and the option-style award vests over time subject to continued employment. Such awards are not immediate purchases or sales and should be interpreted as part of pay/retention arrangements rather than a direct market sentiment signal. Any future exercises or sales of vested shares will generate new filings that could provide additional insight.